Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

Campbell, 2006, The myeloproliferative disorders., N Engl J Med, 355, 2452, 10.1056/NEJMra063728 Tam, 2009, Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis., J Clin Oncol, 27, 5587, 10.1200/JCO.2009.22.8833 Abdulkarim, 2009, AML transformation in 56 patients with Ph- MPD in two well defined populations., Eur J Haematol, 82, 106, 10.1111/j.1600-0609.2008.01163.x Hussein, 2009, Conventional cytogenetics in myelofibrosis: literature review and discussion., Eur J Haematol, 82, 329, 10.1111/j.1600-0609.2009.01224.x Gangat, 2009, Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance., Eur J Haematol, 83, 17, 10.1111/j.1600-0609.2009.01246.x Panani, 2007, Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications., Cancer Lett, 255, 12, 10.1016/j.canlet.2007.02.009 Gangat, 2008, Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates., Eur J Haematol, 80, 197, 10.1111/j.1600-0609.2007.01003.x Reilly, 2008, Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)., Leukemia, 22, 1818, 10.1038/leu.2008.218 Kralovics, 2002, Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera., Exp Hematol, 30, 229, 10.1016/S0301-472X(01)00789-5 Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders., Lancet, 365, 1054, 10.1016/S0140-6736(05)71142-9 James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera., Nature, 434, 1144, 10.1038/nature03546 Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders., N Engl J Med, 352, 1779, 10.1056/NEJMoa051113 Levine, 2005, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis., Cancer Cell, 7, 387, 10.1016/j.ccr.2005.03.023 Pardanani, 2006, MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients., Blood, 108, 3472, 10.1182/blood-2006-04-018879 Szpurka, 2009, UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation., Leukemia, 23, 610, 10.1038/leu.2008.249 Buxhofer-Ausch, 2009, Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis., Eur J Haematol, 82, 161, 10.1111/j.1600-0609.2008.01183.x Delhommeau, 2009, Mutation in TET2 in myeloid cancers., N Engl J Med, 360, 2289, 10.1056/NEJMoa0810069 Tefferi, 2009, TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis., Leukemia, 23, 905, 10.1038/leu.2009.47 Dunbar, 2008, 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies., Cancer Res, 68, 10349, 10.1158/0008-5472.CAN-08-2754 Sanada, 2009, Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms., Nature, 460, 904, 10.1038/nature08240 Carbuccia, 2009, Mutations of ASXL1 gene in myeloproliferative neoplasms., Leukemia, 23, 2183, 10.1038/leu.2009.141 Green, 2010, Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms., N Engl J Med, 362, 369, 10.1056/NEJMc0910063 Jäger, 2010, Deletions of the transcription factor Ikaros in myeloproliferative neoplasms., Leukemia, 24, 1290, 10.1038/leu.2010.99 Thoennissen, 2010, Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms., Blood, 115, 2882, 10.1182/blood-2009-07-235119 Stegelmann, 2010, High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations., Haematologica, 95, 666, 10.3324/haematol.2009.013623 Kralovics, 2006, Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders., Blood, 108, 1377, 10.1182/blood-2005-11-009605 Murphy, 2003, Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex PCR and capillary electrophoresis assay., J Mol Diagn, 5, 96, 10.1016/S1525-1578(10)60458-8 Harutyunyan, 2011, p53 lesions in leukemic transformation., N Engl J Med, 364, 488, 10.1056/NEJMc1012718 Ernst, 2010, Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders., Nat Genet, 42, 722, 10.1038/ng.621 Nikoloski, 2010, Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes., Nat Genet, 42, 665, 10.1038/ng.620 Oh, 2010, Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms., Blood, 116, 988, 10.1182/blood-2010-02-270108 Pardanani, 2010, LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations., Leukemia, 24, 1713, 10.1038/leu.2010.163 Maciejewski, 2008, Whole genome scanning as a cytogenetic tool in hematologic malignancies., Blood, 112, 965, 10.1182/blood-2008-02-130435 Plo, 2008, JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders., Blood, 112, 1402, 10.1182/blood-2008-01-134114 Rossi, 2007, Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age., Nature, 447, 725, 10.1038/nature05862 Vannucchi, 2007, Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia., Blood, 110, 840, 10.1182/blood-2006-12-064287 Laurie, 2006, Inactivation of the p53 pathway in retinoblastoma., Nature, 444, 61, 10.1038/nature05194 Riemenschneider, 2003, Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target., Int J Cancer, 104, 752, 10.1002/ijc.11023 Beer, 2010, Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm., Blood, 115, 2891, 10.1182/blood-2009-08-236596 Cadieux, 2006, Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia., Cancer Res, 66, 9492, 10.1158/0008-5472.CAN-05-4230 Truscott, 2008, p110 CUX1 cooperates with E2F transcription factors in the transcriptional activation of cell cycle-regulated genes., Mol Cell Biol, 28, 3127, 10.1128/MCB.02089-07 Banham, 2001, The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p., Cancer Res, 61, 8820 Kok, 1997, Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes., Adv Cancer Res, 71, 27, 10.1016/S0065-230X(08)60096-2 Hu, 2006, Foxp1 is an essential transcriptional regulator of B cell development., Nat Immunol, 7, 819, 10.1038/ni1358 Golub, 1994, Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation., Cell, 77, 307, 10.1016/0092-8674(94)90322-0 Odero, 2001, Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping., Genes Chromosomes Cancer, 31, 134, 10.1002/gcc.1127 Bohlander, 2005, ETV6: a versatile player in leukemogenesis., Semin Cancer Biol, 15, 162, 10.1016/j.semcancer.2005.01.008 Cavé, 1997, ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia., Leukemia, 11, 1459, 10.1038/sj.leu.2400798 Ding, 2009, AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms., Blood, 114, 5201, 10.1182/blood-2009-06-223982 Tanaka, 1995, An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms., EMBO J, 14, 341, 10.1002/j.1460-2075.1995.tb07008.x